|
Goals
After studying this monograph, the reader should be able to:
- Describe
the prevalence, incidence, etiology, and impact of anemia in patients
with cancer and patients with chronic kidney disease (CKD).
- Discuss
the results and implications of recent clinical studies comparing
various regimens of epoetin alfa and darbepoetin alfa in patients
with cancer or CKD.
- Describe
potential benefits and pitfalls to consider when developing treatment
guidelines, and devise a strategy for successful implementation
of such guidelines.
- Compare
and contrast the recommendations in various authoritative guidelines
for the use of erythropoietic therapies and adapt them for use
in a specific health system.
- Understand
the role of economic analysis as a tool for making contractual
decisions about erythropoietic therapies.
|
